Inhibitors of Akt activity

1. A compound of the formula A:

wherein

R 1 represents phenyl, furyl, thienyl or pyridinyl, any of which groups may be optionally substituted with one, two or three substituents, independently selected from:

a) halogen;

b) C 1-4 alkyl;

c) C 1-4 alkoxy;

d) cyano;

e) di(C 1-4 alkyl)amino;

f) hydroxy;

R 2 represents amino-C 1-6 alkyl, C 1-4 alkylamino-(C 1-6 )alkyl, di(C 1-4 alkyl)amino-(C 1-6 )alkyl, or C 1-4 alkoxy-(C 1-6 )alkyl; and

R 3 is selected from: C 3-7 cycloalkyl and aryl;

or a pharmaceutically acceptable salt or stereoisomer thereof.

2. The compound according to claim 1 of the formula A-I:

wherein

R 2 is as defined in claim 1 ;

R 3 is selected from: C 3-7 cycloalkyl and phenyl,

m is 0, 1, 2 or 3; and

R 5 independently represents halogen, C 1-4 alkyl or C 1-6 alkoxy;

or a pharmaceutically acceptable salt or stereoisomer thereof.

3. A pharmaceutical composition comprising a pharmaceutical carrier, and dispersed therein, a therapeutically effective amount of a compound of claim 1 .

4. A method for treating ovarian, pancreatic and breast cancer which comprises administering to a mammal in need thereof a therapeutically effective amount of a composition of claim 3 .

5. A method for treating ovarian, pancreatic and breast cancer which comprises administering to a mammal in need thereof a therapeutically effective amount of a compound selected from 6-(2-hydroxyethyl)oxy-3,7-diphenyl-[1,2,4]triazolo[4,3-b]pyridazine, 6-(4-hydroxybutyl)oxy-3,7-diphenyl-[1,2,4]triazolo[4,3-b]pyridazine or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

6. A pharmaceutical composition made by combining the compound of claim 1 and a pharmaceutically acceptable carrier.

7. A process for making a pharmaceutical composition comprising combining a compound of claim 1 and a pharmaceutically acceptable carrier.